Show summary Hide summary
Nearly 90,000 bottles of children’s ibuprofen distributed across the United States have been pulled from shelves after the Food and Drug Administration flagged the medicine for possible contamination. The recall, which was recently escalated to a higher-risk classification, raises immediate safety questions for parents and caregivers who may have the product at home.
The recall affects about 89,592 bottles of 100 mg/5 mL Children’s Ibuprofen Oral Suspension produced by Strides Pharma, an India-based manufacturer, on behalf of Taro Pharmaceuticals USA. The liquid was packaged in 4-fluid-ounce bottles and shipped nationwide.
What the FDA found and why the recall was raised
Initial complaints described a gel-like substance and small black particles inside some bottles. After reviewing reports, the FDA reclassified the action this week as a Class II recall, meaning exposure to the affected product could cause temporary or medically reversible health effects, while serious outcomes are considered unlikely.
OpenAI CEO makes amends with Tumbler Ridge community after backlash
Walmart sales trend echoes past recessions: rising risk for consumers
The recall follows consumer reports rather than an identified chemical contaminant; regulators continue to investigate the precise nature and source of the foreign material.
- Product: Children’s Ibuprofen Oral Suspension, 100 mg per 5 mL
- Container size: 4 fluid ounces
- Manufacturer: Strides Pharma, Inc. (manufactured in India for Taro Pharmaceuticals USA)
- Quantity recalled: Approximately 89,592 bottles
- Lot numbers: 7261973A and 7261974A
- Expiration date: January 31, 2027
- Distribution: Nationwide in the United States
What parents and caregivers should do now
If you have a bottle that matches the lot numbers above, stop using it immediately and secure it away from children. Do not attempt to strain or otherwise alter the product.
Parents who are concerned because a child has taken the medicine should contact their healthcare provider for guidance. For non-urgent questions about the recall, consumers can consult FDA resources or reach out to Taro Pharmaceuticals for instructions on disposal or return.
Healthcare professionals and consumers are also encouraged to report any adverse events or unexpected effects after using the product to the FDA’s MedWatch program so regulators can compile a clearer picture of risk.
Context and implications
Recalls of pediatric medications attract heightened attention because children are particularly vulnerable to dosing errors and contaminants. While a Class II designation indicates a lower likelihood of severe harm than the highest recall category, the incident underscores persistent supply-chain and quality-control challenges in pharmaceutical manufacturing.
For now, the practical takeaway for families is straightforward: check bottle labels for the specified lot numbers and expiration date, stop use if there’s a match, and seek medical advice if a child has ingested the recalled suspension.
